Plain-English translation of NCT07342179 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is tracking how your immune system responds to CAR-T cell therapy, a treatment designed to fight multiple myeloma. Researchers will collect blood and bone marrow samples before you receive the treatment and then regularly for up to one year afterward to measure how well your immune cells are working and how long they survive.
CAR-T cell therapy is a promising treatment for multiple myeloma, but doctors still need to better understand how patients' immune systems respond to it. This research will help doctors learn which patients benefit most from the treatment and may improve how this therapy is used in the future.
You likely qualify if…
You likely don't qualify if…
You will have blood samples taken (7 times) and bone marrow samples collected (3 times) from the start of your CAR-T cell therapy through one year afterward. These samples will be sent to a central laboratory where researchers will analyze your immune cells to see how they're responding to the treatment. Your participation involves scheduled sample collection visits over approximately one year.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
France
Poitiers University Hospital
Enrollment target
~60 participants
Started
February 2026
Primary completion
October 2032
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
ARTHUR BOBIN
Poitiers University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.